Through our US-UK network, we source, develop and manage early/mid-stage healthcare technology companies focused on Diagnostics, Digital health and Therapeutics.
We are focused on providing management support for our investments which can involve senior team members at NetScientific taking leadership roles in portfolio companies, in the early stages of investment, to build out dedicated management teams.
In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack
The firm said that it had concluded following the review that a revised strategy was required to reduce its central functions and costs “significantly” so as much of its remaining cash as possible could be allocated to its portfolio companies
Upon satisfaction of the contingent outbound direct investment approval, NetScientific's controlling interest will be 50.4% of Glycotest, calculated on a fully-diluted basis following the closing of the Series A Financing
The AIM-listed firm said the use of Wanda’s existing platform had been shown to predict 90% of patient-level adverse events up to seven days in advance of their occurrence and allows for virtual intervention to prevent such events